治疗腰痛的老年性治疗

IF 12.5 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Science Advances Pub Date : 2025-03-14

Matthew Mannarino, Hosni Cherif, Saber Ghazizadeh, Oliver Wu Martinez, Kai Sheng, Elsa Cousineau, Seunghwan Lee, Magali Millecamps, Chan Gao, Alice Gilbert, Cedric Peirs, Reza Sharif Naeini, Jean A. Ouellet, Laura S. Stone, Lisbet Haglund

{"title":"治疗腰痛的老年性治疗","authors":"Matthew Mannarino, Hosni Cherif, Saber Ghazizadeh, Oliver Wu Martinez, Kai Sheng, Elsa Cousineau, Seunghwan Lee, Magali Millecamps, Chan Gao, Alice Gilbert, Cedric Peirs, Reza Sharif Naeini, Jean A. Ouellet, Laura S. Stone, Lisbet Haglund","doi":"","DOIUrl":null,"url":null,"abstract":"<div >Senescent cells (SnCs) accumulate because of aging and external cellular stress throughout the body. They adopt a senescence-associated secretory phenotype (SASP) and release inflammatory and degenerative factors that actively contribute to age-related diseases, such as low back pain (LBP). The senolytics, o-vanillin and RG-7112, remove SnCs in human intervertebral discs (IVDs) and reduce SASP release, but it is unknown whether they can treat LBP. sparc−/− mice, with LBP, were treated orally with o-vanillin and RG-7112 as single or combination treatments. Treatment reduced LBP and SASP factor release and removed SnCs from the IVD and spinal cord. Treatment also lowered degeneration scores in the IVDs, improved vertebral bone quality, and reduced the expression of pain markers in the spinal cord. Together, our data suggest RG-7112 and o-vanillin as potential disease-modifying drugs for LBP and other painful disorders linked to cell senescence.</div>","PeriodicalId":21609,"journal":{"name":"Science Advances","volume":"11 11","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.science.org/doi/reader/10.1126/sciadv.adr1719","citationCount":"0","resultStr":"{\"title\":\"Senolytic treatment for low back pain\",\"authors\":\"Matthew Mannarino, Hosni Cherif, Saber Ghazizadeh, Oliver Wu Martinez, Kai Sheng, Elsa Cousineau, Seunghwan Lee, Magali Millecamps, Chan Gao, Alice Gilbert, Cedric Peirs, Reza Sharif Naeini, Jean A. Ouellet, Laura S. Stone, Lisbet Haglund\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div >Senescent cells (SnCs) accumulate because of aging and external cellular stress throughout the body. They adopt a senescence-associated secretory phenotype (SASP) and release inflammatory and degenerative factors that actively contribute to age-related diseases, such as low back pain (LBP). The senolytics, o-vanillin and RG-7112, remove SnCs in human intervertebral discs (IVDs) and reduce SASP release, but it is unknown whether they can treat LBP. sparc−/− mice, with LBP, were treated orally with o-vanillin and RG-7112 as single or combination treatments. Treatment reduced LBP and SASP factor release and removed SnCs from the IVD and spinal cord. Treatment also lowered degeneration scores in the IVDs, improved vertebral bone quality, and reduced the expression of pain markers in the spinal cord. Together, our data suggest RG-7112 and o-vanillin as potential disease-modifying drugs for LBP and other painful disorders linked to cell senescence.</div>\",\"PeriodicalId\":21609,\"journal\":{\"name\":\"Science Advances\",\"volume\":\"11 11\",\"pages\":\"\"},\"PeriodicalIF\":12.5000,\"publicationDate\":\"2025-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.science.org/doi/reader/10.1126/sciadv.adr1719\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science Advances\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://www.science.org/doi/10.1126/sciadv.adr1719\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Advances","FirstCategoryId":"103","ListUrlMain":"https://www.science.org/doi/10.1126/sciadv.adr1719","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

衰老细胞（SnCs）由于衰老和外部细胞压力在全身积累。它们采用与衰老相关的分泌表型（SASP），并释放炎症和退行性因子，积极促进与年龄相关的疾病，如腰痛（LBP）。抗衰老药o-香兰素和RG-7112可以去除人椎间盘（IVDs）中的SnCs并减少SASP的释放，但它们是否能治疗腰痛尚不清楚。患有LBP的sparc - / -小鼠口服o-香兰素和RG-7112作为单独或联合治疗。治疗降低了LBP和SASP因子的释放，并从IVD和脊髓中去除SnCs。治疗还降低了ivd的退变评分，改善了椎体骨质量，减少了脊髓疼痛标志物的表达。总之，我们的数据表明RG-7112和o-香兰素是潜在的疾病改善药物，用于治疗LBP和其他与细胞衰老相关的疼痛疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Senolytic treatment for low back pain

查看原文本刊更多论文

Senolytic treatment for low back pain

Senescent cells (SnCs) accumulate because of aging and external cellular stress throughout the body. They adopt a senescence-associated secretory phenotype (SASP) and release inflammatory and degenerative factors that actively contribute to age-related diseases, such as low back pain (LBP). The senolytics, o-vanillin and RG-7112, remove SnCs in human intervertebral discs (IVDs) and reduce SASP release, but it is unknown whether they can treat LBP. sparc^−/− mice, with LBP, were treated orally with o-vanillin and RG-7112 as single or combination treatments. Treatment reduced LBP and SASP factor release and removed SnCs from the IVD and spinal cord. Treatment also lowered degeneration scores in the IVDs, improved vertebral bone quality, and reduced the expression of pain markers in the spinal cord. Together, our data suggest RG-7112 and o-vanillin as potential disease-modifying drugs for LBP and other painful disorders linked to cell senescence.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Science Advances 综合性期刊-综合性期刊

CiteScore

21.40

自引率

1.50%

发文量

1937

审稿时长

29 weeks

期刊介绍： Science Advances, an open-access journal by AAAS, publishes impactful research in diverse scientific areas. It aims for fair, fast, and expert peer review, providing freely accessible research to readers. Led by distinguished scientists, the journal supports AAAS's mission by extending Science magazine's capacity to identify and promote significant advances. Evolving digital publishing technologies play a crucial role in advancing AAAS's global mission for science communication and benefitting humankind.